Skip to content

Author

J. Vietri

We have 2 of 24 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Residual Disparities in US Adults Hospitalized due to All-Cause Pneumonia Following Implementation of Childhood 13-Valent Pneumococcal Conjugate Vaccine in National Immunization Program

Abstract Background Use of 13-valent pneumococcal conjugate vaccine (PCV13) has reduced the burden of pneumococcal disease among both children and adults. Research has indicated that some population subgroups have benefited more than others. This study estimated rates of inpatient all-cause pneumonia among US adults by...

Mark H. Rozenbaum, A. Averin, D. Weycker et al. · 0 citations
Open access Jun 2026

Cost effectiveness and public health impact of PCV20 among adults in France.

PCV20 is a cost-saving alternative to the PCV13 → PPV23 sequence for at-risk adults in France and provides substantial public health gains and represents a highly cost-effective strategy relative to commonly cited French vaccine HTA benchmarks.

S. Fiévez, Mélanie Menara, E. Blanc et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.